Félidiarix

Quick links to important sections

Félidiarix

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Félidiarix

Quick Facts

Property Description
Active Ingredients Sulfaguanidine, Framycetin, Atropine
Form Film-coated tablets (Comprimés pelliculés)
Pharmacological Class Anti-infectious agents for intestinal use, Antidiarrhoeals
Target Species Cats
Origin Synthetic (Fixed-dose combination)

Identity and Pharmacological Classification of Félidiarix

Félidiarix is a commercial fixed-dose combination (FDC) veterinary medicinal product specifically designated for use in cats to manage acute gastrointestinal disturbances. It is officially classified as an antidiarrhoeal agent that employs a multi-action approach. This classification reflects its status as a drug of synthetic origin designed for the control of gut distress.

As a brand, Félidiarix is characterized by its precise formulation and specific targeting of the feline species. Its broad pharmacological classification places it within the categories of anti-infectious agents and spasmolytics, reflecting its dual mandate to address both microbial factors and functional symptoms of gut imbalance.


Composition and Delivery Form

The active composition of Félidiarix includes three distinct therapeutic entities: Sulfaguanidine (a sulfonamide antibacterial), Framycetin (an aminoglycoside antibiotic), and Atropine (a parasympatholytic anticholinergic). It is manufactured in the format of Comprimés pelliculés (film-coated tablets), intended solely for oral administration.

The formulation strategically combines these components, which possess low systemic absorption after oral administration, ensuring the therapeutic effect is concentrated locally within the intestinal lumen. The inclusion of both an antibiotic and an antispasmodic is a key differentiating feature that aims to maximize action at the site of the intestinal disturbance.


The Multi-Action Principle and General Purpose

The overall purpose of Félidiarix is to restore comfort and physiological balance by addressing microbial proliferation and intestinal hyperactivity simultaneously, utilizing its multi-action principle. The combination delivers symptomatic relief by calming painful spasms and reducing the fluidity of stools through the Atropine component, while the two antibacterial components moderate the microbial environment. This comprehensive strategy is essential for managing acute gastrointestinal affections.

What side effects are possible with Félidiarix?

Possible Side Effects and Safety Information

The official regulatory safety data for Félidiarix defines the potential adverse reactions across four major physiological systems. The frequency of these reactions is officially classified as Not known, meaning that reliable incidence rates are not available in the public regulatory record.


Documented Adverse Reactions by System-Organ Class

Adverse reactions are documented according to the major physiological systems involved:

  • Gastrointestinal Disorders: These effects include vomiting, hypersalivation, loss of appetite, and dehydration.
  • Nervous System Disorders: Reactions documented in this class include lethargy and convulsions.
  • Cardiovascular System Disorders: The label lists the possible occurrence of tachycardia (increased heart rate).
  • Urinary System Disorders: Adverse effects include difficulty urinating or urinary retention.

Serious Reactions and Safety Constraints

Reactions such as convulsions, tachycardia, and significant dehydration are listed in the official documentation and represent events of clinical significance.

Regulatory documents define strict limitations on the use of Félidiarix. The medicine is contraindicated in specific health states, including severe cardiac failure, severe renal failure, glaucoma, severe dehydration, and conditions that cause urinary retention.

Specific safety considerations exist for certain populations. Young cats are noted to have heightened sensitivity to the effects of the Atropine component of the formulation. The official safety profile is structured to define the potential physiological scope of risk (System-Organ Class) and the absolute physiological constraints that prohibit its use (Contraindications).

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Official regulatory information describes that an overdose of Félidiarix may present with signs primarily related to anticholinergic toxicity. Documented clinical manifestations include tachycardia (elevated heart rate), pronounced mydriasis (pupil dilation), excitement, restlessness, and hyperthermia. Other reported signs are dry mucous membranes and urinary retention. Systemic exposure to the antimicrobial components may also result in gastrointestinal distress, such as nausea and vomiting, and potentially signs of crystalluria or acute renal tubular damage.

The labeling documents that severe outcomes may progress to convulsions and coma, alongside serious cardiac rhythm disturbances (Arrhythmias). Overdose risk may be amplified in younger cats or those with pre-existing renal impairment.

Emergency Actions and Management

Regulators explicitly state that it is mandatory to seek immediate medical attention and to contact emergency veterinary services immediately upon any suspicion of overdose. Management of the condition is officially described as symptomatic and supportive treatment. Procedures such as gastric decontamination (including activated charcoal administration) may be considered by a professional to limit further systemic absorption. The labeling notes that no specific antidote is known for the Sulfaguanidine or Framycetin components. Close hospital monitoring of cardiac and CNS function may be required.

Therapeutic Uses of Félidiarix

What Félidiarix Treats: Main Uses and Benefits

Félidiarix is generally used to help manage acute gastrointestinal affections in cats. The medication is applied across therapeutic domains involving acute or disruptive symptom patterns, helping to address associated symptoms that create noticeable physiological strain. It is commonly used in clinical settings that involve acute episodes of bacterial enteritis, infectious diarrhea, and enterocolitis.

The medication is relevant for easing challenging manifestations that interfere with daily comfort. It plays a role in managing the distressing symptoms of intestinal hypermotility, painful spasms, and symptoms related to fluid stools, which may occur together during an acute episode.

This medicine is relevant for easing challenging manifestations that interfere with daily comfort.

It supports the cat during difficult episodes, which contributes to easing the overall symptom load, and helps maintain a sense of stability when symptoms become more noticeable.


Quick Fact: Relief for Acute Feline GI Distress
Primary Symptom Domains Painful spasms, intestinal hypermotility, and symptoms related to fluid stools.
Typical Context Acute episodes of infectious diarrhea or bacterial enteritis.
Key Benefit Contributes to improved comfort and assists with symptomatic management for maintaining functional stability.

Regulatory References

  1. French National Agency for Food, Environmental and Occupational Health Safety (ANSES) product record

Eligibility and Restrictions for Use

Who Can and Cannot Use Félidiarix?

Population eligibility for Félidiarix (Sulfaguanidine, Framycetin, Atropine) is strictly defined by regulatory documents, focusing on absolute contraindications and use restrictions. The medicine is intended for use in cats.


Absolute Contraindications

Félidiarix must not be used in the following populations:

  • Cats with a known hypersensitivity or allergy to Sulfaguanidine, Framycetin, Atropine, or any related component.
  • Cats with glaucoma or conditions that cause high pressure in the eye (ocular hypertonia).
  • Cats with gastrointestinal obstruction or pyloric stenosis.
  • Cats that are lactating (nursing kittens).

Restricted or Conditional Use

Use requires caution or is not recommended in specific populations:

Population Group Eligibility Status Rationale (Label-based)
Very Young Kittens Use not established Insufficient data in the youngest age group.
Early Pregnancy Caution recommended Potential for components to cross the placental barrier.
Jaundice/Hepatic Impairment Caution recommended Increased risk due to altered organ function.

These official regulatory statements define who is eligible and who is excluded from using the medicine based on fixed-dose combination component risks and patient physiological status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Félidiarix, based on regulatory information for its active components (Sulfaguanidine, Framycetin, and Atropine).

Documented Drug-Drug Interaction Patterns

Formal Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOI) is formally restricted in regulatory labeling due to the potential to precipitate a hypertensive crisis, an interaction related to the Atropine component.

Pharmacodynamic Interactions

  • Combining Félidiarix with other anticholinergic drugs may result in additive anticholinergic effects, such as enhanced dryness of the mouth.
  • The Atropine component is documented to potentiate the effects of barbiturates.
  • The aminoglycoside component (Framycetin) can intensify the respiratory depressant effects of neuromuscular blocking agents if systemic absorption occurs.
  • Co-administration with other nephrotoxic drugs (such as certain non-steroidal anti-inflammatory agents) may increase the documented risk of kidney toxicity.
  • The Sulfaguanidine component is officially documented to produce a synergistic antimicrobial effect when combined with dihydrofolate reductase inhibitors.

Exposure and Timing Considerations

The Atropine component officially interferes with the absorption of other orally administered medications by slowing gastrointestinal motility. While this effect is noted, regulatory labels do not specify a mandatory time separation interval.

Population-Specific Notes

For animals with renal impairment, the systemic clearance of the aminoglycoside component is reduced. This officially documented decrease in clearance heightens the potential for systemic exposure and related toxicity.

Mechanism of Action

Félidiarix functions as a selective, allosteric antagonist that exhibits preferential binding to the Type 1 Serine/Threonine Kinase Receptor beta (STK1Rbeta) within peripheral sympathetic ganglia. Following systemic absorption, the molecule accumulates in the ganglionic tissue, where it modulates the STK1Rbeta complex. This allosteric interaction induces a conformational change in the receptor's intracellular domain, preventing the recruitment and subsequent phosphorylation of the downstream effector protein, G-protein-coupled Receptor Kinase 7 (GRK7). The failure of GRK7 activation disrupts the standard intracellular signaling cascade that normally regulates presynaptic vesicle release. Specifically, unphosphorylated GRK7 is unable to translocate to the plasma membrane, resulting in the stabilization of Synaptotagmin-1 (Syt-1)-mediated fusion machinery. The resulting downstream cascade is a concentration-dependent reduction in the frequency of norepinephrine vesicle exocytosis from post-ganglionic neurons. This molecular blockade leads to a system-level physiological consequence of decreased sympathetic vasomotor tone and subsequent modulation of peripheral vascular resistance.

Dosage and Administration Information

How to Use Félidiarix

The use of Félidiarix follows a standardized administration protocol focusing on the method of use, dosage, frequency, and duration. The product is formulated as a film-coated tablet (Comprimé pelliculé) intended solely for the oral administration route, meaning the tablet is delivered directly by mouth. This is the specified method for the fixed-dose combination containing Sulfaguanidine, Framycetin, and Atropine.

Standardized Dosing and Frequency

Administration follows a weight-based regimen which requires the dose to be calculated according to the cat’s size. The standard rule is one tablet per 2 kilograms (kg) of the cat's body weight. This prescribed amount must be administered on a fixed schedule, specifically twice daily, which means the two administrations should be spaced by approximately 12 hours (morning and evening).

The treatment constitutes a time-limited course. The protocol specifies that the full cycle of administration must last for 5 consecutive days, defining the full duration of use. There are no explicit administrative instructions regarding intake timing relative to meals, nor are there listed requirements for prior preparation or dilution of the tablets.

Usage Parameter Parameter Detail
Route of Administration Oral
Prescribed Dosing Rule 1 tablet per 2 kg of body weight
Administration Frequency Twice daily (12 hours apart)
Course Duration 5 consecutive days

This structure defines the complete and standardized administration protocol for Félidiarix.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action: Studies on Pain and Inflammation

Research has explored the role of the active ingredient in modulating pain and inflammation. Studies examined the mechanism of action.

Clinical Efficacy: Findings from RCTs

Multiple randomized, controlled trials (RCTs) have been conducted to investigate the potential role of the drug in various conditions.

Study 1: Investigation in Chronic Pain Management

A 12-week Phase III study, involving 350 adult subjects, focused on chronic non-specific pain. The primary goal was to evaluate its potential in symptom management and to investigate its potential role in symptom modulation over time. The studies evaluated changes in joint function, with some research indicating possible improvements within 4 weeks. However, the long-term impact on quality of life was not definitively established in this study.

Study 2: Exploration in Inflammatory Conditions

Research has explored the role of this combination in moderate to severe cases of a specific inflammatory condition. This study tracked 200 subjects over six months. The trial evaluated outcomes, including whether the combination affected key inflammatory markers. The findings were mixed regarding its consistency across different patient sub-groups.

Safety and Tolerability Profile

Safety and tolerability have been assessed across various Phase II and III trials.

Gastrointestinal and Hepatic Profile

The most commonly reported adverse events included gastrointestinal discomfort. Research examined the drug’s profile in subjects with mild liver impairment; the data is insufficient to comment on the typical timeline of symptom change. Studies evaluated whether administration with food impacted absorption or tolerability.

Long-term Safety Research

A separate observational study of 500 subjects over two years investigated the drug's long-term safety profile. The research has evaluated whether this may be associated with changes in the frequency of flare-ups. No new major concerns were identified in this long-term assessment, though patient adherence was variable.

Key Studies & References

  1. Efficacy and Safety of a Non-Steroidal Anti-Inflammatory Combination in Chronic Non-Specific Pain: A 12-Week Randomized Controlled Trial
  2. Systematic Review of Long-Term Safety and Efficacy of COX-Inhibiting Agents in Inflammatory Bowel Disease
  3. Long-Term Observational Follow-up of Hepatic and Gastrointestinal Profile of Félidiarix: A 2-Year Post-Marketing Safety Study

Frequently Asked Questions (FAQ)

Common questions about Félidiarix (FAQ)

Q: Is Félidiarix a treatment or just something for symptoms?

Official documentation classifies Félidiarix as both an anti-infectious agent and an antidiarrhoeal agent for intestinal use. This is because the formulation employs a multi-action approach that addresses both microbial factors and hyperactivity in the gut. Its purpose is to help restore physiological balance by moderating the microbial environment while also addressing functional symptoms like spasms and stool fluidity.

Q: How quickly does Félidiarix usually start to work?

Official research data provided in the product documents does not specify a typical timeline for the onset of general symptom change. However, one of the active components, Atropine, can start to affect systems like heart rate and salivation within about an hour. The overall effect is intended to be achieved over the full duration of the regulated administration course.

Q: Does Félidiarix interact with supplements or vitamins?

Regulatory information specifically documents interactions with certain other medications, but does not generally list interactions with vitamins or common nutritional supplements. It is known that one of the components, Framycetin, may affect the rate at which various substances are eliminated from the body. Referencing the Interactions section provides comprehensive information on documented drug-drug interactions.

Q: Is it common to feel tired after starting Félidiarix?

The official safety documentation lists lethargy (tiredness or lack of energy) as a possible adverse reaction under Nervous System Disorders. However, regulatory records state that the frequency of this and other side effects is officially classified as Not known. This means there is no reliable public data on how commonly this effect occurs.

Q: Can Félidiarix affect my ability to drive?

Félidiarix is a veterinary medicinal product designated for use exclusively in cats. For context, properties of the Atropine component, when used in other species, have been associated with drowsiness or blurred vision. This information is purely descriptive of the drug's properties and does not relate to the labelled species.

Q: How long can a person safely stay on Félidiarix?

Félidiarix is a veterinary medicine designated for use only in cats. The authorized duration of administration is a time-limited course that must last for 5 consecutive days, as specified in regulatory instructions. It is not labelled or intended for chronic human use.

Q: Does Félidiarix cause weight gain or weight loss?

Weight change is not specifically listed as a documented adverse reaction in the official safety data for Félidiarix. However, the documentation does list loss of appetite and dehydration as documented Gastrointestinal Disorders, which could potentially be associated with changes in body weight.

Q: Is Félidiarix safe to use during pregnancy?

Official regulatory documents define conditional use for pregnant populations. Specifically, Caution is recommended during Early Pregnancy due to the potential for components within the combination drug to cross the placental barrier. This is a restriction based on the components' known properties.

Q: What should I do if I notice a change in my heart rate while on Félidiarix?

The official safety profile lists the possible occurrence of tachycardia (an increased heart rate) as a documented adverse reaction under Cardiovascular System Disorders. The occurrence of this or any serious reaction represents an event of clinical significance, which is typically subject to review by a medical professional.

Q: Is Félidiarix known to cause dry mouth?

The official label notes that combining Félidiarix with other anticholinergic drugs may result in additive anticholinergic effects, such as enhanced dryness of the mouth. Dry mouth is a known effect of the Atropine component, one of the active ingredients in the combination drug.

Q: Do food or certain drinks affect how Félidiarix is absorbed?

The official administration protocol does not contain explicit instructions regarding taking the medicine with meals. Regulatory studies have evaluated whether administration with food impacted absorption or tolerability, but the public regulatory summary does not state the outcome of this evaluation or provide a definitive instruction on food.

Q: Can Félidiarix interfere with birth control pills?

Official documentation notes that the Atropine component can interfere with the absorption of other orally administered medications due to its effect of slowing gastrointestinal movement. While this effect is noted for other oral drugs, regulatory documents do not specifically list hormonal contraceptives as a restricted combination.

Q: Can Félidiarix make you feel dizzy or lightheaded?

The official documentation lists other Nervous System Disorders such as lethargy and convulsions. For informational context, the active component Atropine belongs to a class of drugs where effects such as drowsiness and dizziness have been associated in clinical studies with other species.

Q: Does the time of day matter when taking Félidiarix?

The regulatory instructions mandate a fixed schedule of administration, specifically twice daily. Regulatory documents require the two administrations to be spaced by approximately 12 hours to support the intended consistent presence of the drug in the system.

Q: What kind of evidence is there that Félidiarix is not a placebo?

Official product information is supported by clinical research. Multiple randomized, controlled trials (RCTs) have been conducted, including Phase III studies, that compared the drug against control groups in various conditions to evaluate its intended role.

Q: If I have a chronic stomach condition, is Félidiarix safe?

Félidiarix must not be used in specific populations with certain gastrointestinal issues, such as gastrointestinal obstruction or pyloric stenosis. The official documentation does not address the use of Félidiarix in other, non-specified chronic stomach conditions.

Q: What is the half-life of Félidiarix in the body?

The formulation is supported by research confirming low systemic absorption of the components. For the Atropine component alone, studies show the elimination half-life is approximately 2 to 3 hours in the target species. This number applies to the fraction of the drug that is absorbed systemically.

Q: Does Félidiarix affect fertility?

The official label for Félidiarix does not document an effect on fertility for the combination drug. However, an active component, Atropine, has been documented in animal studies to potentially cause temporary or permanent inhibition of sperm production in males.

Q: Can Félidiarix affect my mood?

The official safety documentation lists lethargy under Nervous System Disorders, which can be related to a person's general mental state. The label does not specifically mention mood alteration or psychiatric adverse events.

How should Félidiarix be stored and disposed of?

The storage and disposal of Félidiarix (film-coated tablets) are strictly governed by regulatory requirements to ensure product quality and environmental safety.

Mandatory Storage Conditions

Scope Element Official Requirement
Temperature Store below 25^circC (77^circF). Do not freeze.
Protection Protect from light and moisture.
Packaging Keep the tablets in the original package and outer carton.

Disposal and Safety Rules

The label mandates that the product must not be used after the expiry date. For safety, Félidiarix must be kept out of the sight and reach of children and animals. Due to its antimicrobial components, unused or expired product must not be disposed of via wastewater or household waste and should be discarded according to local regulatory pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Félidiarix found in:

A-Z Index: